Acer Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Acer Therapeutics

25/02/2023 03:14

* Acer Therapeutics Inc  ACER.OQ   ACER.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
28 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Acer Therapeutics
Inc is
for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acer
Therapeutics
Inc is $8.5​, above​ its last closing price of $2.14. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.65       -0.68      -0.31     Beat    54.6
 Jun. 30 2022  -0.56       -0.57      -0.17     Beat    70.2
 Mar. 31 2022  -0.40       -0.41      -0.64     Missed  -54.2​
 Dec. 31 2021  -0.01       -0.01      -0.31     Missed  -3,000
 ​​Sep.        -0.28       -0.28      -0.23     Beat    17.9
 30 2021                                                
 Jun. 30 2021  -0.36       -0.36      -0.23     Beat    35.8​
 Mar. 31 2021  -0.44       -0.44      -0.11     Beat    74.9
 Dec. 31 2020  -0.42       -0.41      -0.50     Missed  -22.7
 This summary was machine generated February 25 at 03:14 GMT. 
All figures in US dollars  unless otherwise stated